Compare Novartis AG (NVS) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs VanEck Semiconductor ETF — how do they compare? Novartis AG trades at $139.7 (market cap $262.28B), while VanEck Semiconductor ETF trades at $570.43. The key difference: Novartis AG pays a 3.45% dividend while VanEck Semiconductor ETF pays none, and VanEck Semiconductor ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | SMH | |
|---|---|---|
Market Cap | $262.28B | — |
Sector | Health | — |
52-Week High | $168.62 | $668.91 |
52-Week Low | $121.80 | $300.83 |
Enterprise Value | $303.60B | — |
Dividend Yield | 3.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
SMH trades at $573.73, up 1.19% with a bullish technical outlook supported by moving averages and positive momentum indicators. The semiconductor ETF benefits from strong AI infrastructure demand, with recent NVIDIA earnings and industry expansion driving investor interest. Institutional activity shows continued accumulation, including a $678,000 position by Greenland Capital Management.
Outlook remains positive given AI-driven semiconductor demand, though risks include potential tariff impacts and market volatility. The ETF's diversified exposure to chip leaders offers growth potential while mitigating single-stock risk, supported by Wall Street's constructive stance on the sector's long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
